The Effect of Budesonide/formoterol Maintenance and Reliever Therapy on the Risk of Severe Asthma Exacerbations Following Episodes of High Reliever Use: an Exploratory Analysis of Two Randomised, Controlled Studies with Comparisons to Standard...

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2012 Jul 24

PMID 22816878

Citations 13

Authors

Roland Buhl

Piotr Kuna

Matthew J Peters

Tomas L G Andersson

Ian P Naya

Stefan Peterson

Klaus F Rabe

Affiliations

Soon will be listed here.

Abstract

Background: Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), supplemented by a short-acting β2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-dose treatment in reducing severe exacerbations while achieving similar or better asthma control in other regards. Exacerbations may be reduced by the use of budesonide/formoterol as reliever medication during periods of unstable asthma. We examined the risk of a severe exacerbation in the period after a single day with high reliever use.

Methods: Episodes of high reliever use were quantified and exacerbations occurring post-index day with these episodes were examined post hoc in two double-blind studies comparing the efficacy and safety of budesonide/formoterol maintenance and reliever therapy (Symbicort SMART™, Turbuhaler®) 160/4.5 μg twice daily plus as needed with similar or higher maintenance doses of ICS/LABA plus SABA or formoterol.

Results: Budesonide/formoterol maintenance and reliever therapy significantly reduced the risk of episodes of high reliever use (>6 inhalations/day) vs. all alternative ICS/LABA regimens. With conventional fixed-dose treatment the need for exacerbation treatment within 21 days ranged from 6.0-10.1% of days post-index for all regimens compared with 2.5-3.4% of days with budesonide/formoterol maintenance and reliever therapy.

Conclusions: Budesonide/formoterol maintenance and reliever therapy reduces the incidence of high reliever episodes and the exacerbation burden immediately following these episodes vs. alternative ICS/LABA plus SABA regimens at up to double the maintenance dose of ICS.

Trial Registration: These studies do not have registration numbers as they were conducted before clinical trial registration was required.

Citing Articles

Patient response to the management during the acute presentation of cough variant Asthma: Retrospective cohort study.

Ibrahim Arif S, Amer Y, Adnan Alkamal T, Abdulrahman Binsaeed M, Ibrahim Arif B, Dhaifallah Albaqami M Saudi J Biol Sci. 2023; 30(12):103875.

PMID: 38058763 PMC: 10696240. DOI: 10.1016/j.sjbs.2023.103875.

A Call for the United States to Accelerate the Implementation of Reliever Combination Inhaled Corticosteroid-Formoterol Inhalers in Asthma.

Krings J, Gerald J, Blake K, Krishnan J, Reddel H, Bacharier L Am J Respir Crit Care Med. 2022; 207(4):390-405.

PMID: 36538711 PMC: 9940146. DOI: 10.1164/rccm.202209-1729PP.

Asthma management in low and middle income countries: case for change.

Mortimer K, Reddel H, Pitrez P, Bateman E Eur Respir J. 2022; 60(3).

PMID: 35210321 PMC: 9474897. DOI: 10.1183/13993003.03179-2021.

Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study.

Chipps B, Albers F, Reilly L, Johnsson E, Cappelletti C, Papi A BMJ Open Respir Res. 2021; 8(1).

PMID: 34887317 PMC: 8663093. DOI: 10.1136/bmjresp-2021-001077.

Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes.

Reddel H, Bacharier L, Bateman E, Brightling C, Brusselle G, Buhl R Eur Respir J. 2021; 59(1).

PMID: 34667060 PMC: 8719459. DOI: 10.1183/13993003.02730-2021.

References

Molimard M, Naline E, Zhang Y, Le Gros V, Begaud B, Advenier C . Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J. 1998; 11(3):583-8. View

Foresi A, Morelli M, Catena E . Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest. 2000; 117(2):440-6. DOI: 10.1378/chest.117.2.440. View

OByrne P, Bisgaard H, Godard P, Pistolesi M, Palmqvist M, Zhu Y . Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2004; 171(2):129-36. DOI: 10.1164/rccm.200407-884OC. View

Matz J, Emmett A, Rickard K, Kalberg C . Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol. 2001; 107(5):783-9. DOI: 10.1067/mai.2001.114709. View

Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M . The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol. 2006; 119(2):322-7. DOI: 10.1016/j.jaci.2006.10.018. View

Chapman K, Barnes N, Greening A, Jones P, Pedersen S . Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax. 2010; 65(8):747-52. PMC: 2975956. DOI: 10.1136/thx.2009.128504. View

Fitzgerald J, Gibson P . Asthma exacerbations . 4: Prevention. Thorax. 2006; 61(11):992-9. PMC: 2121160. DOI: 10.1136/thx.2005.045195. View

Kuna P, Peters M, Manjra A, Jorup C, Naya I, Martinez-Jimenez N . Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007; 61(5):725-36. PMC: 1920547. DOI: 10.1111/j.1742-1241.2007.01338.x. View

Spitzer W, Suissa S, Ernst P, Horwitz R, Habbick B, Cockcroft D . The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992; 326(8):501-6. DOI: 10.1056/NEJM199202203260801. View

10.

Rodrigo G . Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest. 2006; 130(5):1301-11. DOI: 10.1378/chest.130.5.1301. View

11.

Lanes S, Garcia Rodriguez L, Huerta C . Respiratory medications and risk of asthma death. Thorax. 2002; 57(8):683-6. PMC: 1746414. DOI: 10.1136/thorax.57.8.683. View

12.

Paggiaro P, Dente F, Morelli M, Bancalari L, Di Franco A, Giannini D . Postallergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics. Am J Respir Crit Care Med. 1994; 149(6):1447-51. DOI: 10.1164/ajrccm.149.6.8004297. View

13.

Barnes P . Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007; 29(3):587-95. DOI: 10.1183/09031936.00080306. View

14.

van Veen A, Weller F, Wierenga E, Jansen H, Jonkers R . A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther. 2003; 16(3):153-61. DOI: 10.1016/S1094-5539(03)00003-8. View

15.

Tattersfield A, Postma D, Barnes P, Svensson K, Bauer C, OByrne P . Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med. 1999; 160(2):594-9. DOI: 10.1164/ajrccm.160.2.9811100. View

16.

Vogelmeier C, DUrzo A, Pauwels R, Merino J, Jaspal M, Boutet S . Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J. 2005; 26(5):819-28. DOI: 10.1183/09031936.05.00028305. View

17.

Bousquet J, Boulet L, Peters M, Magnussen H, Quiralte J, Martinez-Aguilar N . Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007; 101(12):2437-46. DOI: 10.1016/j.rmed.2007.07.014. View

18.

Rodrigo G, Plaza Moral V, Marcos L, Castro-Rodriguez J . Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther. 2008; 22(1):9-19. DOI: 10.1016/j.pupt.2008.10.008. View

19.

Sears M, Radner F . Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med. 2009; 103(12):1960-8. DOI: 10.1016/j.rmed.2009.08.007. View

20.

Eisner M, Lieu T, Chi F, Capra A, Mendoza G, Selby J . Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J. 2001; 17(2):233-40. DOI: 10.1183/09031936.01.17202330. View